UPDATED JULY 3: The Food and Drug Administration has approved Kisunla (generic name donanemab), a new Alzheimer’s drug developed by Eli Lilly. The published data…
The Food and Drug Administration has decided to postpone its decision on the approval of Eli Lilly’s candidate Alzheimer’s drug, donanemab. The delay has…
On Friday, February 16th, at 10 a.m. PT/1 p.m. ET, Lou Niles joins Being Patient Live Talks to discuss his experience taking part in…
American pharmaceutical company Eli Lilly announced in May 2023 that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to…
After almost two decades of stagnation, two new drugs for Alzheimer’s have hit the market in the last three years. The approval of Biogen…
According to drugmaker Eli Lilly, the FDA has rejected the company’s application for the FDA’s “Accelerated Approval” designation for experimental Alzheimer’s drug donanemab. The…
In Being Patient’s LiveTalk series, Dr. David Weidman, associate medical director for research at the Banner Alzheimer’s Institute, shares insights on Eli Lilly’s investigational Alzheimer’s…
This weekend, Eli Lilly and Company presented detailed results of its phase 2 TRAILBLAZER-ALZ trial, showing that its investigational drug donanemab — monoclonal antibody…
(UPDATED Sat. March 13, 2021) In January, excitement rippled through the Alzheimer’s community with drugmaker Eli Lilly and Company’s announcement that their experimental drug…
The initial results from Eli Lilly and Co’s Phase 2 clinical trial for experimental Alzheimer’s drug donanemab provide much needed hope for the Alzheimer’s…
Eisai and Biogen’s Alzheimer’s drug Leqembi (generic name lecanemab) was the first fully-FDA approved disease-modifying treatment for early-stage Alzheimer’s disease in United States history,…
Brain Talk, hosted by Being Patient founder Deborah Kan and journalist Mark Niu, digs into the topics that matter most to the Being Patient…
When ancient Greek soldiers laid their mythical siege upon the city of Troy, they struggled to break through the city’s impenetrable walls. To finally…
There currently no cure or treatment that can completely halt or reverse Alzheimer’s pathology in the brain. One of the biggest obstacles: Even after…
With the 2024 FDA approval of Eli Lilly’s Kisunla for early-stage Alzheimer’s disease, there are now two fairly similar anti-amyloid on the market in…